Tempus Study Validates PurIST® Algorithm for Pancreatic Cancer Therapy
Real-world evidence demonstrates PurIST’s ability to guide first-line treatment decisions and improve outcomes for patients with advanced pancreatic ductal adenocarcinoma (PDAC) Tempus AI, Inc. (NASDAQ:...
